Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873725 | 0.74 | TSHR (0.45) | ALDH1A1TSHRLMNAHTT | |
| SCHEMBL11154023 | 0.74 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNAHTT | |
| SCHEMBL1640508 | 0.72 | HTT (0.45) | ALDH1A1TSHRHTTFGFR4 | |
| SCHEMBL9879834 | 0.72 | ALDH1A1 (0.34) | ALDH1A1TSHRHTT | |
| SCHEMBL17818667 | 0.72 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNAHTT | |
| SCHEMBL6831466 | 0.72 | ALDH1A1 (0.38) | ALDH1A1TSHRHTT | |
| SCHEMBL17818669 | 0.70 | ALDH1A1 (0.33) | ALDH1A1TSHRHTT | |
| Silver SCHEMBL17818665 | 0.70 | ALDH1A1 (0.33) | ALDH1A1TSHRHTT | |
| Hydrochloric Acid SCHEMBL8646283 | 0.70 | HTT (0.44) | ALDH1A1TSHRHTTFGFR4 | |
| SCHEMBL5984299 | 0.69 | HTT (0.39) | ALDH1A1TSHRHTTFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-20200121654-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-04-23 | — | — | US | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | ALDH1A1 670/4885TSHR 4278/4885LMNA 1060/4885 |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | ALDH1A1 957/4885TSHR 4574/4885LMNA 626/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | ALDH1A1 670/4885TSHR 4278/4885LMNA 1060/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20200121654-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | ALDH1A1 670/4885TSHR 4278/4885LMNA 1060/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | ALDH1A1 320/4885TSHR 4710/4885LMNA 1247/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | ALDH1A1 320/4885TSHR 4710/4885LMNA 1247/4885 |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | ALDH1A1 110/4885TSHR 4429/4885LMNA 371/4885 |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ALDH1A1 371/4885TSHR 4243/4885LMNA 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.